Racial differences in the systemic inflammatory response to prostate cancer
暂无分享,去创建一个
A. Rundle | B. Rybicki | S. Williamson | D. Tang | N. Gupta | D. Chitale | O. Kryvenko | Oleksandr N. Kryvenko | Yalei Chen | Sudha M. Sadasivan | K. Bobbitt
[1] E. Giovannucci,et al. Inflammatory serum markers and risk and severity of prostate cancer: The PROCA‐life study , 2020, International journal of cancer.
[2] M. Shaul,et al. Tumour-associated neutrophils in patients with cancer , 2019, Nature Reviews Clinical Oncology.
[3] K. Egan,et al. Sociodemographic and lifestyle factors associated with the neutrophil-to-lymphocyte ratio. , 2019, Annals of epidemiology.
[4] L. Dennis,et al. A Systematic Review and Meta-analysis of Associations between Clinical Prostatitis and Prostate Cancer: New Estimates Accounting for Detection Bias , 2019, Cancer Epidemiology, Biomarkers & Prevention.
[5] S. M. Warli,et al. Systemic Inflammatory Response in Predicting Prostate Cancer: The Diagnostic Value of Neutrophil-To-Lymphocyte Ratio , 2019, Open access Macedonian journal of medical sciences.
[6] Hao Peng,et al. Prognostic significance of elevated pretreatment systemic inflammatory markers for patients with prostate cancer: a meta-analysis , 2019, Cancer Cell International.
[7] S. Avcı,et al. Lymphocyte-to-monocyte ratio is a valuable marker to predict prostate cancer in patients with prostate specific antigen between 4 and 10 ng/dl. , 2019, Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica.
[8] V. Mirone,et al. Neutrophil, Platelets, and Eosinophil to Lymphocyte Ratios Predict Gleason Score Upgrading in Low-Risk Prostate Cancer Patients , 2018, Urologia Internationalis.
[9] M. Terris,et al. Neutrophil, lymphocyte and platelet counts, and risk of prostate cancer outcomes in white and black men: results from the SEARCH database , 2018, Cancer Causes & Control.
[10] M. Abolhasani,et al. The role of blood neutrophil count and the neutrophil-to-lymphocyte ratio as a predictive factor for prostate biopsy results , 2018, Urologia.
[11] L. Ying,et al. Prognostic Significance of Pre-Operative Monocyte-to-Lymphocyte Ratio in Lung Cancer Patients Undergoing Radical Surgery , 2018, Laboratory medicine.
[12] Yanqing Wang,et al. Systemic immune‐inflammation index predicts the combined clinical outcome after sequential therapy with abiraterone and docetaxel for metastatic castration‐resistant prostate cancer patients , 2018, The Prostate.
[13] D. Moreira,et al. Inflammation on Prostate Needle Biopsy is Associated with Lower Prostate Cancer Risk: A Meta‐Analysis , 2017, The Journal of urology.
[14] E. Monti,et al. The association between prostatitis and prostate cancer. Systematic review and meta-analysis. , 2017, Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica.
[15] E. Morii,et al. Peripheral blood monocyte count reflecting tumor‐infiltrating macrophages is a predictive factor of adverse pathology in radical prostatectomy specimens , 2017, The Prostate.
[16] Yingwei Xue,et al. Monocyte to lymphocyte ratio predicts survival in patients with advanced gastric cancer undergoing neoadjuvant chemotherapy , 2017, OncoTargets and therapy.
[17] I. Thompson,et al. A Prospective Study of Chronic Inflammation in Benign Prostate Tissue and Risk of Prostate Cancer: Linked PCPT and SELECT Cohorts , 2017, Cancer Epidemiology, Biomarkers & Prevention.
[18] O. Bischof,et al. Cytokine-induced senescence for cancer surveillance , 2017, Cancer and Metastasis Reviews.
[19] X. Wan,et al. Preoperative Monocyte-to-Lymphocyte Ratio in Peripheral Blood Predicts Stages, Metastasis, and Histological Grades in Patients with Ovarian Cancer12 , 2016, Translational oncology.
[20] K. Ru,et al. Elevated neutrophil-to-lymphocyte ratio and monocyte-to-lymphocyte ratio and decreased platelet-to-lymphocyte ratio are associated with poor prognosis in multiple myeloma , 2016, Oncotarget.
[21] N. Nonomura,et al. Serum monocyte fraction of white blood cells is increased in patients with high Gleason score prostate cancer , 2016, Oncotarget.
[22] H. Feigelson,et al. Serum cholesterol trajectories in the 10 years prior to lymphoma diagnosis , 2017, Cancer Causes & Control.
[23] G. Oates,et al. Systemic Inflammation in Midlife: Race, Socioeconomic Status, and Perceived Discrimination. , 2017, American journal of preventive medicine.
[24] A. Sciarra,et al. Prognostic value of inflammation in prostate cancer progression and response to therapeutic: a critical review , 2016, Journal of Inflammation.
[25] P. Tassone,et al. Tumor infiltrating T lymphocytes expressing FoxP3, CCR7 or PD-1 predict the outcome of prostate cancer patients subjected to salvage radiotherapy after biochemical relapse , 2016, Cancer biology & therapy.
[26] Xintao Li,et al. Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Localized and Advanced Prostate Cancer: A Systematic Review and Meta-Analysis , 2016, PloS one.
[27] X. Gu,et al. Prognostic significance of neutrophil-to-lymphocyte ratio in prostate cancer: evidence from 16,266 patients , 2016, Scientific Reports.
[28] Neil Pearce,et al. Analysis of matched case-control studies , 2016, British Medical Journal.
[29] Yi Xiao,et al. Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Prostate Cancer , 2016, Medicine.
[30] A. Rundle,et al. Racial differences in the relationship between clinical prostatitis, presence of inflammation in benign prostate and subsequent risk of prostate cancer , 2016 .
[31] J. Oh,et al. Association of the neutrophil-to-lymphocyte ratio and prostate cancer detection rates in patients via contemporary multi-core prostate biopsy , 2015, Asian journal of andrology.
[32] N. Hamidi,et al. Evaluation of neutrophil-to-lymphocyte ratio prior to prostate biopsy to predict biopsy histology: Results of 1836 patients. , 2015, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.
[33] D. Taussky,et al. Neutrophil count is associated with survival in localized prostate cancer , 2015, BMC Cancer.
[34] T. Yamanaka,et al. Neutrophil-to-lymphocyte ratio predicts prostatic carcinoma in men undergoing needle biopsy , 2015, Oncotarget.
[35] J. Meeker,et al. Statistical methods for modeling repeated measures of maternal environmental exposure biomarkers during pregnancy in association with preterm birth , 2015, Environmental Health.
[36] K. Ceylan,et al. Benign prostatic hyperplasia and prostate cancer differentiation via platelet to lymphocyte ratio. , 2015, Cancer biomarkers : section A of Disease markers.
[37] E. Taioli,et al. Average Values and Racial Differences of Neutrophil Lymphocyte Ratio among a Nationally Representative Sample of United States Subjects , 2014, PloS one.
[38] S. Albayrak,et al. Is the neutrophil-lymphocyte ratio an indicator of progression in patients with benign prostatic hyperplasia? , 2014, Asian Pacific journal of cancer prevention : APJCP.
[39] N. Nonomura,et al. White blood cell count is positively associated with benign prostatic hyperplasia , 2014, International journal of urology : official journal of the Japanese Urological Association.
[40] G. Andriole,et al. Baseline prostate inflammation is associated with a reduced risk of prostate cancer in men undergoing repeat prostate biopsy: Results from the REDUCE study , 2014, Cancer.
[41] A. D. De Marzo,et al. The role of inflammation in prostate cancer. , 2014, Advances in experimental medicine and biology.
[42] Junjian Liu,et al. The Role of Prostatitis in Prostate Cancer: Meta-Analysis , 2013, PloS one.
[43] K. Ronkainen,et al. Prediagnostic circulating markers of inflammation and risk of prostate cancer , 2013, International journal of cancer.
[44] T. Tammela,et al. Histological inflammation and risk of subsequent prostate cancer among men with initially elevated serum prostate‐specific antigen (PSA) concentration in the Finnish prostate cancer screening trial , 2013, BJU international.
[45] S. Clarke,et al. The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. , 2013, Critical reviews in oncology/hematology.
[46] Deepa Naishadham,et al. Cancer statistics for African Americans, 2013 , 2013, CA: a cancer journal for clinicians.
[47] Aliccia Bollig-Fischer,et al. Genes Associated with Prostate Cancer Are Differentially Expressed in African American and European American Men , 2013, Cancer Epidemiology, Biomarkers & Prevention.
[48] Jennifer R. Rider,et al. CD4 helper T cells, CD8 cytotoxic T cells, and FOXP3+ regulatory T cells with respect to lethal prostate cancer , 2013, Modern Pathology.
[49] K. Beullens,et al. Results From a Prospective Cohort Study , 2013 .
[50] Jennifer G. Robinson,et al. Genome-wide association and population genetic analysis of C-reactive protein in African American and Hispanic American women. , 2012, American journal of human genetics.
[51] K. Fujita,et al. Low serum neutrophil count predicts a positive prostate biopsy , 2012, Prostate Cancer and Prostatic Diseases.
[52] S. Albelda,et al. Tumor-associated neutrophils: friend or foe? , 2012, Carcinogenesis.
[53] A. Rundle,et al. Inflammation and preneoplastic lesions in benign prostate as risk factors for prostate cancer , 2012, Modern Pathology.
[54] G. D. de Bock,et al. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis , 2011, British Journal of Cancer.
[55] H. Markus,et al. Population differences in proinflammatory biology: Japanese have healthier profiles than Americans , 2011, Brain, Behavior, and Immunity.
[56] A. Sica. Role of tumour-associated macrophages in cancer-related inflammation. , 2010, Experimental oncology.
[57] W. Gerald,et al. Copy number and gene expression differences between African American and Caucasian American prostate cancer , 2010, Journal of Translational Medicine.
[58] J. Witte,et al. Prostatitis, Sexually Transmitted Diseases, and Prostate Cancer: The California Men's Health Study , 2007, PloS one.
[59] Brady T. West,et al. Analyzing Longitudinal Data With the Linear Mixed Models Procedure in SPSS , 2009, Evaluation & the health professions.
[60] Robyn L Prueitt,et al. Tumor immunobiological differences in prostate cancer between African-American and European-American men. , 2008, Cancer research.
[61] L. Bégin,et al. Chronic inflammation is negatively associated with prostate cancer and high‐grade prostatic intraepithelial neoplasia on needle biopsy , 2007, International journal of clinical practice.
[62] John T. Wei,et al. Sexual behavior, sexually transmitted diseases and prostatitis: the risk of prostate cancer in black men. , 2006, The Journal of urology.
[63] T. Erlinger,et al. C-reactive protein levels and subsequent cancer outcomes: results from a prospective cohort study. , 2006, European journal of cancer.
[64] Paolo Vineis,et al. Design Options for Molecular Epidemiology Research within Cohort Studies , 2005, Cancer Epidemiology Biomarkers & Prevention.
[65] L. Dennis,et al. Epidemiologic association between prostatitis and prostate cancer. , 2002, Urology.
[66] Judith D. Singer,et al. Using SAS PROC MIXED to Fit Multilevel Models, Hierarchical Models, and Individual Growth Models , 1998 .
[67] J. Eastham,et al. Clinical Characteristics and Biopsy Specimen Features in African-American and White Men Without Prostate Cancer , 1998 .
[68] S. Thompson. Advances in experimental medicine and biology , 1996 .